Silverback terminates President/CSO and CFO; appoints interim CFO ahead of merger

ARS Pharmaceuticals, Inc.

Terminated Valerie Odegard (President/CSO) and Jonathan Piazza (CFO), effective Sept 2, 2022, to extend cash runway.
Odegard and Piazza entered consulting agreements at $350/hour (max 20 hrs/wk) through merger close or Nov 30, 2022.
Equity awards continue vesting during consulting period; options remain exercisable.
Russ Hawkinson appointed Interim CFO; he also serves as SVP Finance and principal accounting officer.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Valerie Odegard

President and Chief Scientific Officer

SPRY · ARS Pharmaceuticals, Inc.

Effective: 2022-09-02
Filed: September 2, 2022, 7:59 PM ET

On September 1, 2022, the board of directors of Silverback Therapeutics, Inc. (“Silverback”) approved the termination of employment of Valerie Odegard, Ph.D., our President and Chief Scientific Officer, and Jonathan Piazza, our Chief Financial Officer, effective as of September 2, 2022

Appointed (interim)

Russ Hawkinson

Interim Chief Financial Officer

SPRY · ARS Pharmaceuticals, Inc.

Effective: 2022-09-02
Filed: September 2, 2022, 7:59 PM ET

Effective as of the Transition Date, Russ Hawkinson has been appointed to serve as Silverback’s Interim Chief Financial Officer and principal financial officer.

Departed (interim)

Jonathan Piazza

Chief Financial Officer

SPRY · ARS Pharmaceuticals, Inc.

Effective: 2022-09-02
Successor: Russ Hawkinson
Filed: September 2, 2022, 7:59 PM ET

On September 1, 2022, the board of directors of Silverback Therapeutics, Inc. (“Silverback”) approved the termination of employment of Valerie Odegard, Ph.D., our President and Chief Scientific Officer, and Jonathan Piazza, our Chief Financial Officer, effective as of September 2, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Valerie Odegard was terminated as President and Chief Scientific Officer at ARS Pharmaceuticals, Inc..

Action: terminated
Role: President and Chief Scientific Officer

Exact text from the filing

On September 1, 2022, the board of directors of Silverback Therapeutics, Inc. (“Silverback”) approved the termination of employment of Valerie Odegard, Ph.D., our President and Chief Scientific Officer, and Jonathan Piazza, our Chief Financial Officer, effective as of September 2, 2022

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Russ Hawkinson was appointed as Interim Chief Financial Officer at ARS Pharmaceuticals, Inc..

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

Effective as of the Transition Date, Russ Hawkinson has been appointed to serve as Silverback’s Interim Chief Financial Officer and principal financial officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jonathan Piazza was terminated as Chief Financial Officer at ARS Pharmaceuticals, Inc..

Action: terminated
Role: Chief Financial Officer

Exact text from the filing

On September 1, 2022, the board of directors of Silverback Therapeutics, Inc. (“Silverback”) approved the termination of employment of Valerie Odegard, Ph.D., our President and Chief Scientific Officer, and Jonathan Piazza, our Chief Financial Officer, effective as of September 2, 2022

View on SEC.gov

ARS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-237900

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.